HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (26) Citing Articles via Google Scholar Google Scholar Articles by Konstantinopoulos, P. A. Articles by Lehmann, D. F. Search for Related Content PubMed PubMed Citation Articles by Konstantinopoulos, P. A. Articles by Lehmann, D. F.

The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding

From SUNY Upstate Medical University, Syracuse, New York.

The premature suspension of the Alzheimer Disease Anti-inflammatory Prevention (ADAPT) and the Adenoma Prevention with Celecoxib (APC) trials prompted intense review of the cardiovascular safety profile of selective and nonselective cyclooxygenase (COX) inhibitors. This article reviews the current state of selective COX-2 inhibitors, discusses the mechanistic evidence underlying the cardiovascular risk associated with selective COX-2 inhibition, outlines the pharmacodynamics of aspirin effects on platelets and the interference of propionic acid derivatives (ibuprofen and naproxen) with these effects, and poses that aspirin confounding may have led to the erroneous conclusion of naproxen-associated adverse cardiovascular outcomes in the ADAPT trial. Finally, recommendations regarding selective COX-2 inhibitors and appropriate timing of aspirin coadministration with traditional NSAIDs are proposed in relevance to patient safety and future trial design.

Key Words: COX-2 inhibitors • NSAIDs • cardiac risk • aspirin

Address for reprints: David F. Lehmann, PharmD, MD, FCP, SUNY Upstate Medical University, 750 E. Adams Street, CWB, Room 322, Syracuse, NY 13210.

This article has been cited by other articles:

				P. A. Konstantinopoulos, M. V. Karamouzis, and A. G. Papavassiliou Effect of Aspirin Use on Thiazolidinediones and Cardiovascular Events JAMA, April 2, 2008; 299(13): 1539 - 1539. [Full Text] [PDF]

				I. G. E. Zarraga and E. R. Schwarz Coxibs and Heart Disease: What We Have Learned and What Else We Need to Know J. Am. Coll. Cardiol., January 2, 2007; 49(1): 1 - 14. [Abstract] [Full Text] [PDF]

				M. Stafford-Smith Hurry up and slow down: Lessons in drug development from the COX-2 inhibitors/Se hater et ralentir: les lecons a tirer de la production des inhibiteurs de la COX-2. Can J Anesth, October 1, 2006; 53(10): 973 - 977. [Full Text] [PDF]

				S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747. [Abstract] [Full Text] [PDF]

				M B Forrester Celecoxib exposures reported to Texas poison control centers from 1999 to 2004 Human and Experimental Toxicology, May 1, 2006; 25(5): 261 - 266. [Abstract] [PDF]

				R. C. Harris and M. D. Breyer Update on Cyclooxygenase-2 Inhibitors Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 236 - 245. [Abstract] [Full Text] [PDF]

				A. Kardosh, N. Soriano, Y.-T. Liu, J. Uddin, N. A. Petasis, F. M. Hofman, T. C. Chen, and A. H. Schonthal Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib Blood, December 15, 2005; 106(13): 4330 - 4338. [Abstract] [Full Text] [PDF]